Home › Funds › Patient Square Capital LP › COGT
Patient Square Capital LP position in COGT
COGENT BIOSCIENCES INC · Health Care
Patient Square Capital LP reported holding 361,927 shares of COGT (COGENT BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$11.6M, representing 1.85% of its reported portfolio and ranking #14 among its reported holdings. Patient Square Capital LP has disclosed COGT holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Patient Square Capital LP's COGT position evolved
Patient Square Capital LP first disclosed a stake in COGT in Q4 2025 at 317,372 shares (US$11.3M). The position peaked in Q1 2026 at 596,000 shares, worth US$22.9M. Across 4 filings, Patient Square Capital LP increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 361,927 shares valued at US$11.6M — a reduction of -63,073 shares quarter over quarter.. Notable position changes include a 88% increase in Q1 2026 (shares were roughly flat over the following quarter), a 29% trim in Q2 2026 (shares fell 17% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 317.37K | $11.27M | New |
| Q1 2026 | 596.00K | $22.94M | Add |
| Q2 2026 | 425.00K | $16.45M | Reduce |
| Q3 2026 | 361.93K | $11.59M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About COGT and 13F data
COGT (COGENT BIOSCIENCES INC) is a Health Care company. 56 other funds we track also report a position in COGT — the largest reported positions include Fairmount Funds Management LLC (US$213.0M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$193.7M), TCG Crossover Management, LLC (US$187.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding COGT
- Fairmount Funds Management LLC 5.50M sh · $212.98M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 5.01M sh · $193.74M · Q2 2026
- TCG Crossover Management, LLC 4.85M sh · $187.87M · Q2 2026
- Kynam Capital Management, LP 3.67M sh · $141.92M · Q2 2026
- Commodore Capital LP 3.05M sh · $118.03M · Q2 2026
- Octagon Capital Advisors LP 2.35M sh · $90.94M · Q2 2026
- RTW INVESTMENTS, LP 2.31M sh · $89.36M · Q2 2026
- Deep Track Capital, LP 2.00M sh · $77.40M · Q2 2026
- Venrock Adviser, LLC 1.64M sh · $63.55M · Q2 2026
- EMERALD ADVISERS, LLC 1.61M sh · $51.67M · Q3 2026
- Siren, L.L.C. 1.61M sh · $51.53M · Q3 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 1.57M sh · $50.42M · Q3 2026
More on Patient Square Capital LP
FAQ
How long has Patient Square Capital LP held COGT?
Patient Square Capital LP has disclosed COGT holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Patient Square Capital LP's current position in COGT?
As of Q3 2026, Patient Square Capital LP holds 361.93K shares of COGT (COGENT BIOSCIENCES INC), valued at $11.59M, representing 1.85% of its reported portfolio and ranking #14.
Has Patient Square Capital LP been buying or selling COGT?
In the latest 13F filing (Q3 2026), Patient Square Capital LP reduced its position in COGT. The position peaked in Q1 2026 at 596.00K shares.
Which other funds hold COGT?
Other major institutional holders of COGT include Fairmount Funds Management LLC, DEERFIELD MANAGEMENT COMPANY, L.P., TCG Crossover Management, LLC, among 56 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.